Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

Hyperuricemia-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hyperuricemia-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hyperuricemia-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hyperuricemia-Pipeline Review, H1 2017



Executive Summary

Hyperuricemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia-Pipeline Review, H1 2017, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperuricemia-Overview

Hyperuricemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperuricemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperuricemia-Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

AstraZeneca Plc

CymaBay Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

Nobelpharma Co Ltd

Polaris Pharmaceuticals Inc

Teijin Pharma Ltd

Hyperuricemia-Drug Profiles

(allopurinol + lesinurad)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLN-346-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arhalofenate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FYU-981-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-Uricase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPH-367-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2500-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2700-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPCX-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegadricase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verinurad-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperuricemia-Dormant Projects

Hyperuricemia-Discontinued Products

Hyperuricemia-Product Development Milestones

Featured News & Press Releases

Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat

Jan 04, 2017: Ironwood Announces New Drug Application for DUZALLO (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review

Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricemia and Predicts Savings for NHS Scotland

May 23, 2016: Teijin Pharma's Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia

Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6-11

Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe

Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat

Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy's

Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric

Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat

Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat

Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea

May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan

Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Hyperuricemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Hyperuricemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hyperuricemia-Pipeline by Allena Pharmaceuticals Inc, H1 2017

Hyperuricemia-Pipeline by AstraZeneca Plc, H1 2017

Hyperuricemia-Pipeline by CymaBay Therapeutics Inc, H1 2017

Hyperuricemia-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Hyperuricemia-Pipeline by Nippon Chemiphar Co Ltd, H1 2017

Hyperuricemia-Pipeline by Nobelpharma Co Ltd, H1 2017

Hyperuricemia-Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Hyperuricemia-Pipeline by Teijin Pharma Ltd, H1 2017

Hyperuricemia-Dormant Projects, H1 2017

Hyperuricemia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Allena Pharmaceuticals Inc, AstraZeneca Plc, CymaBay Therapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Nippon Chemiphar Co Ltd, Nobelpharma Co Ltd, Polaris Pharmaceuticals Inc, Teijin Pharma Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand